Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Genexa Inc. is navigating 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and multiple art units. This distribution shows that while the portfolio is small, it involves multiple technical perspectives within the pharmaceutical sector, which may complicate the alignment of prosecution strategies.
STEVENS, MARK V acts as the busiest examiner, holding 2 pending office actions. This concentration suggests that the majority of the company's current prosecution outcomes depend on the decisions of a single examiner. Practitioners should analyze the specific preferences and past allowance rates of this examiner given their influence over the majority of the 3 total pending matters. Because the biotechnology sector often involves complex technical hurdles, the concentration of multiple actions with this examiner could either streamline the path to allowance or create a significant bottleneck.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEVENS, MARK V | 2 | 65.5% | +41.6% |
| ALAWADI, SARAH | 1 | 37.5% | +38.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18619076 | SOLID PHARMACEUTICAL TABLET | STEVENS, MARK V | 23d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18201375 | SYRUP FORMULATION OR SUSPENSION | ALAWADI, SARAH | 2d overdue |
| 18619076 | SOLID PHARMACEUTICAL TABLET | STEVENS, MARK V | 23d |
| 18886197 | DIPHENHYDRAMINE SYRUP FORMULATION OR SUSPENSION | STEVENS, MARK V | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18886197 | DIPHENHYDRAMINE SYRUP FORMULATION OR SUSPENSION | STEVENS, MARK V | — | §102§103§112DP | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18619076 | SOLID PHARMACEUTICAL TABLET | STEVENS, MARK V | 1613 | §101§102§103§112Other | Non-Final OA | 23d | Pending | Mar 27, 2024 |
| 18201375 | SYRUP FORMULATION OR SUSPENSION | ALAWADI, SARAH | 1619 | §103Other | Non-Final OA | 2d overdue | Pending | May 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial